title: Comparison of HTK and hypertonic citrate to intraarterial cooling in human non-heart-beating kidney donors.
abstract: Intraarterial cooling (IAC) of non-heart-beating donors (NHBD) for renal donation requires a cheap, low-viscosity solution. HTK contains a high hydrogen ion buffer level that theoretically should reduce the observable acidosis associated with ongoing anaerobic metabolism. A retrospective comparison of all retrieved NHBD kidneys as well as of viability on the Organ Recovery Systems Lifeporter machine perfusion circuit was performed with respect to the preservation solution HTK or Marshall's HOC. Forty-two NHBD kidneys (19 HTK and 23 HOC) were machine perfused between February 2004 and May 2005. Most of the HTK kidneys were obtained from uncontrolled donors (12 vs 5; Fisher exact test, P = .01). As a consequence, the glutathione-s-transferase viability assay (411 vs 292 IU/L, P = .12) and the lactate concentrations (2.33 vs 1.94 mmol/L, P = .13) were higher among the HTK cohort. There was evidence of greater buffering capacity in HTK, since the lactate:hydrogen ion ratios were consistently lower during the first 2 perfusion hours (1 hour P = .03, 2 hour P = .02). A linear regression analysis confirmed that this was related to the IAC solution (ANCOVA, P < .001). All controlled donor kidneys passed viability testing and were transplanted. In contrast, 83% (10/12) of the uncontrolled donor kidneys preserved with HTK passed the viability test and were transplanted, compared with only 20% (1/5) of the HOC-treated comparators (Fisher exact test, P = .03). It may be concluded that the postulated advantages of improved pH buffering with HTK appear to have clinical relevance.
authors.affiliation: The Liver/Renal Unit, The Freeman Hospital, Newcastle-upon-Tyne, United Kingdom.
authors.forename: C H
authors.initials: CH
authors.lastname: Wilson
authors.forename: J F
authors.initials: JF
authors.lastname: Asher
authors.forename: A
authors.initials: A
authors.lastname: Gupta
authors.forename: D
authors.initials: D
authors.lastname: Vijayanand
authors.forename: H
authors.initials: H
authors.lastname: Wyrley-Birch
authors.forename: S
authors.initials: S
authors.lastname: Stamp
authors.forename: D A
authors.initials: DA
authors.lastname: Rix
authors.forename: N
authors.initials: N
authors.lastname: Soomro
authors.forename: D M
authors.initials: DM
authors.lastname: Manas
authors.forename: B C
authors.initials: BC
authors.lastname: Jaques
authors.forename: R
authors.initials: R
authors.lastname: Peaston
authors.forename: D
authors.initials: D
authors.lastname: Talbot
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D015331:Cohort Studies; D005260:Female; D005947:Glucose; D006323:Heart Arrest; D006801:Humans; D006982:Hypertonic Solutions; D007668:Kidney; D008297:Male; D008353:Mannitol; D008875:Middle Aged; D019188:Organ Preservation Solutions; D018579:Patient Selection; D010477:Perfusion; D011189:Potassium Chloride; D011343:Procaine; D014019:Tissue Donors; D020858:Tissue and Organ Harvesting / Q000379:methods
chemical_list: C039984:Bretschneider cardioplegic solution; D006982:Hypertonic Solutions; C054581:Marshall's citrate solution; D019188:Organ Preservation Solutions; D008353:Mannitol; D011343:Procaine; D011189:Potassium Chloride; D005947:Glucose